NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

AIDS Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



HIV/AIDS



New HIV/AIDS study findings reported from K.G. Saskova and co-authors



November 3rd, 2008

According to a study from Prague, Czech Republic, "Lopinavir (LPV) is a second-generation HIV protease inhibitor (PI) designed to overcome resistance development in patients undergoing long-term antiviral therapy. The mutation of isoleucine at position 47 of the HIV protease (PR) to alanine is associated with a high level of resistance to LPV."

"In this study, we show that recombinant PR containing a single I47A substitution has the inhibition constant (K-i) value for lopinavir by two orders of magnitude higher than for the wild-type PR. The addition of the I47A substitution to the background of a multiply mutated PR species from an AIDS patient showed a...


Source: AIDS Weekly (2008-11-03)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login